10-Q: Azitra Inc. Reports Third Quarter 2024 Results, Progresses Clinical Trials

Azitra Inc. announced its third quarter 2024 financial results, highlighting advancements in clinical trials for its lead product candidates and ongoing research and development efforts.

Summary

• Azitra Inc., a synthetic biology company focused on skin therapeutics, reported a net loss of $1.0 million for the third quarter of 2024, compared to a net loss of $1.9 million for the same period in 2023.
• The company's total revenue for the quarter was $0, a decrease from $310,700 in the third quarter of 2023, due to reduced service revenue from a related party.
• Operating expenses increased to $2.9 million in Q3 2024 from $2.3 million in Q3 2023, driven by higher research and development costs and general and administrative expenses.
• Research and development expenses rose to $1.0 million in Q3 2024, up from $548,524 in Q3 2023, reflecting increased clinical trial activities.
• General and administrative expenses increased to $1.9 million in Q3 2024 from $1.7 million in Q3 2023, primarily due to costs associated with being a public company.
• The company reported a significant gain of $4.0 million in the change in fair value of warrants, which positively impacted other income.
• For the nine months ended September 30, 2024, Azitra reported a net loss of $6.6 million, compared to a net loss of $8.8 million for the same period in 2023.
• The company's cash and cash equivalents stood at $7.3 million as of September 30, 2024, with total assets of $9.8 million and working capital of $6.3 million.
• Azitra completed follow-on public offerings in February and July 2024, raising net proceeds of $4.3 million and $9.1 million, respectively.
• The company dosed its first patient in the Phase 1b clinical trial for ATR-12 in August 2024 and expects initial safety results in early 2025.
• Azitra received FDA clearance to commence a Phase 1/2 clinical trial for ATR-04 in August 2024 and obtained Fast Track designation in September 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and some positive financial developments, the company's financial position and going concern issues raise significant concerns. The sentiment is cautiously negative due to the financial risks.

Positives

• The company has made significant progress in advancing its clinical programs, with the first patient dosed in the ATR-12 trial and IND clearance for the ATR-04 trial.
• The company secured Fast Track designation for ATR-04, which could expedite its development.
• The company successfully raised additional capital through follow-on public offerings.
• The company reported a significant gain in the change in fair value of warrants.
• The net loss for the third quarter of 2024 was lower than the net loss for the same period in 2023.

Negatives

• The company's revenue decreased significantly due to reduced service revenue from a related party.
• Operating expenses increased substantially, driven by higher research and development and general and administrative costs.
• The company has an accumulated deficit of $55.2 million and a loss from operations of $8.6 million for the nine months ended September 30, 2024.
• The company's management has expressed substantial doubt about its ability to continue as a going concern without raising additional capital.
• The company identified a material weakness in its internal controls related to a lack of adequate segregation of accounting functions.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company is subject to risks common to the pharmaceutical industry, including development of new technologies by competitors, dependence on key personnel, and regulatory compliance.
• The company's reliance on third-party manufacturers and the protection of proprietary technology pose significant risks.
• The company's ability to convert successful development work into a commercial license with Bayer is dependent on factors outside of its control.
• The company identified a material weakness in its internal controls related to a lack of adequate segregation of accounting functions.

Future Outlook

The company expects to report initial clinical safety results for ATR-12 in early 2025 and commence a Phase 1b trial for ATR-04 in the fourth quarter of 2024. The company plans to perform lead optimization and IND-enabling studies for ATR-01 in 2024, targeting an IND filing in early 2026. The company intends to seek additional funding through various financing sources.

Management Comments

• Management has determined there is substantial doubt about the company's ability to continue as a going concern based on its lack of revenue from commercial operations, significant losses, and the need to raise additional capital to support ongoing operations.
• Management plans to continue to raise funds through equity and debt financing to fund operating and working capital needs.
• Management believes that the company has established a unique position in advancing the development of biologics for precision dermatology.

Industry Context

Azitra is operating in the competitive biopharmaceutical industry, focusing on precision dermatology. The company's approach of using engineered proteins and live biotherapeutic products is innovative, but it faces competition from other companies developing treatments for similar skin conditions. The company's partnerships with academic institutions and its proprietary microbial library provide a competitive advantage.

Comparison to Industry Standards

• Azitra's approach of using genetically engineered bacteria for therapeutic use in dermatology is relatively novel compared to traditional pharmaceutical companies.
• The company's focus on orphan diseases like Netherton syndrome aligns with a trend in the industry to address unmet medical needs.
• The company's reliance on public offerings for funding is common among early-stage biotech companies, but it also highlights the need for consistent progress to maintain investor confidence.
• Compared to larger pharmaceutical companies, Azitra's revenue is minimal, reflecting its early stage of development. Companies like Amgen, Regeneron, and AbbVie have established revenue streams from commercialized products, while Azitra is still in the clinical trial phase.
• Azitra's research and development expenses are typical for a company in its stage, but they are significantly lower than those of established pharmaceutical companies. For example, companies like Pfizer and Merck spend billions annually on R&D.
• The company's cash position is relatively low compared to larger biotech companies, which often have substantial cash reserves to fund their operations and clinical trials. Companies like Gilead and Biogen maintain large cash balances to support their extensive pipelines.

Related Party Transactions

• Total related party revenue was $0 and $7,500 for the three and nine months ended September 30, 2024, respectively. Total related party revenue was $310,700 and $596,000 for the three and nine months ended September 30, 2023, respectively.
• Accounts receivable due from the related party was $0 and $90,000 at September 30, 2024 and December 31, 2023, respectively.
• In September 2022, the Company entered into a convertible promissory note totaling $4,350,000 of which $4,000,000 was attributable to an entity who was also an investor in the Company's Series A, A-1, and B Preferred Stock financing.
• In July 2024, Bayer was no longer considered a related party as their holdings in the Company no longer exceeded 5% of the total outstanding common stock.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment if the company cannot secure additional funding.
• Employees may be affected by potential cost-cutting measures or layoffs if the company's financial situation does not improve.
• Customers and patients may benefit from the development of new therapies, but the company's financial instability could delay or halt these developments.
• Suppliers and creditors face the risk of non-payment if the company's financial situation worsens.

Next Steps

• The company expects to report initial clinical safety results for ATR-12 in early 2025.
• The company plans to commence a Phase 1b trial for ATR-04 in the fourth quarter of 2024.
• The company is planning to perform lead optimization and IND-enabling studies for ATR-01 in 2024, targeting an IND filing in early 2026.
• The company will seek additional funding through various financing sources.

Key Dates

Keywords

biopharmaceutical, dermatology, clinical trials, engineered proteins, live biotherapeutic products, Netherton syndrome, EGFRi, ichthyosis vulgaris, microbial library, genetic engineering